Minneapolis, MN USA  Jul 19 2021 /EINPresswire.com/ – Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program. Luminary Therapeutics is a clinical stage allogeneic cellular therapy company. Its gamma

Minneapolis, MN USA  Feb 23 2021 – Bio-Techne Corporate (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies.

Minneapolis, July 7, 2020 —Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for